专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明授权

US06686373B2 Pyrazoloquinolinone derivatives as protein kinase C inhibitors 失效
标题翻译：吡唑啉酮衍生物作为蛋白激酶C抑制剂
公开(公告)号：US06686373B2
公开(公告)日：2004-02-03
申请号：US10191593
申请日：2002-07-09
申请人： Kiyoshi Kawamura , Sachiko Mihara , Seiji Nukui , Chikara Uchida
发明人： Kiyoshi Kawamura , Sachiko Mihara , Seiji Nukui , Chikara Uchida
IPC分类号： A61K314745
CPC分类号： C07D471/04
摘要： This invention provides a compound of the formula (I): or the pharmaceutically acceptable salts thereof wherein the dashed lines represent optional double bonds; C1, C2, C3 and C4 are carbon atom; R1 is C1-4 alkyl; R2 is H, amino, etc.; R3 is H, halo-CH2—, C2-8 alkyl or Q1-, wherein said C2-8 alkyl is optionally substituted with up to 3 substituents selected from halo, C1-3 alkyl, R4(R5)N, etc.; R4 is H, C1-7 alkyl, etc.; R5 is H, C1-7alkyl, etc.; R6 and R7 are independently selected from H and C1-4 alkyl; R8 is aryl or heteroaryl; Q1 is a 4-12 membered monocyclic or bicyclic aromatic, partially saturated or fully saturated ring optionally containing up to 4 heteroatoms selected from O, N and S, and is optionally substituted with halo, C1-4 alkyl, etc.; Y5, Y6, Y7 and Y8 are hydrogen; Y1, Y2, Y3 and Y4 are independently selected from hydrogen, halo, etc.; Q2 is a 5-12 membered monocyclic or bicyclic aromatic, partially saturated or fully saturated ring optionally containing up to 3 heteroatoms selected from O, N and S, and is optionally substituted with halo, C1-4alkyl-, etc.; These compounds have protein kinase C inhibitory activity and thus are useful for the treatment of neuropathic pain, acute or chronic inflammatory pain, auditory deficiency (synaptic repair), or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.
摘要翻译：本发明提供式（I）化合物或其药学上可接受的盐，其中虚线表示任选的双键; C 1，C 2，C 3和C 4是碳原子; R 1是C 1-4烷基; R 2是H，氨基等; R 3是H，卤代-CH 2 - ，C 2-8烷基或Q 1 - ，其中所述C 2-8烷基任选被至多3个选自卤素，C 1-3烷基，R 4，（R 5）N等; R 4是H，C 1-7烷基等; R 5是H，C 1-7烷基等; R 6和R 7独立地选自H和C 1-4烷基; R 8是芳基或杂芳基; Q 1是4-12元单环或双环芳族，部分饱和或完全饱和的环，任选地含有至多4个选自O，N和S的杂原子，并且任选地被卤素，C 1-4烷基等取代; Y 5，Y 6，Y 7和Y 8是氢; Y 1，Y 2，Y 3和Y 4独立地选自氢，卤素等; Q 2是5-12元单环或双环芳族，部分饱和或完全饱和的环，任选地含有至多3个选自O，N和S的杂原子，并且任选被卤素，C 1-4烷基等取代; 这些化合物具有蛋白激酶C抑制活性，因此可用于治疗哺乳动物，特别是人类的神经性疼痛，急性或慢性炎性疼痛，听觉缺陷（突触修复）等。本发明还提供了包含上述化合物的药物组合物。

12. 发明授权

US06624162B2 Imidazopyridine compounds as 5-HT4 receptor modulators 失效
标题翻译：咪唑并吡啶化合物作为5-HT4受体调节剂
公开(公告)号：US06624162B2
公开(公告)日：2003-09-23
申请号：US10251109
申请日：2002-09-20
申请人： Chikara Uchida , Hirohide Noguchi , Alan Stobie , Geoffrey Gymer , David Fenwick
发明人： Chikara Uchida , Hirohide Noguchi , Alan Stobie , Geoffrey Gymer , David Fenwick
IPC分类号： A61K31437
CPC分类号： C07D471/04
摘要： This invention provides a compound of the formula (I): or the pharmaceutically acceptable salts thereof wherein R1 is hydrogen, halo or alkyl; R2 and R3 are independently hydrogen, alkyl, alkenyl, alkynyl, aminoalkyl or hydroxyalkyl; or R2 and R3 taken together with the nitrogen atom to which they are attached may form hetrocyclic; R4 is hydrogen, halo, acyl, amino, amido, aryl, arylalkyl, or heteroaryl; R5 is hydrogen, halo, alkyl alkenyl, alkynyl, acyl, amino, amido, aryl, arylalkyl, or heteroaryl; R6 is hydrogen, alkyl or alkoxyalkyl; X is NR9 wherein R9 is hydrogen or alkyl; and Y is (CR7R8)n wherein n is an integer from 0 to 5. These compounds have 5-HT4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, Functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.
摘要翻译：本发明提供式（I）化合物或其药学上可接受的盐，其中R 1是氢，卤素或烷基; R 2和R 3独立地是氢，烷基，烯基，炔基，氨基烷基或羟烷基; 或R 2和R 3与它们所连接的氮原子一起可以形成环状的; R 4是氢，卤素，酰基，氨基，酰氨基，芳基，芳基烷基或杂芳基; R 5是氢，卤素，烷基烯基，炔基，酰基，氨基，酰氨基，芳基，芳基烷基或杂芳基; R 6是氢，烷基或烷氧基烷基; X是NR 9，其中R 9是氢或烷基; 并且Y是（CR 7 R 8）n，其中n是0至5的整数。这些化合物具有5-HT 4受体结合活性，因此可用于治疗胃食管反流病，非溃疡性消化不良，功能性消化不良，肠易激综合征等。本发明还提供了包含上述化合物的药物组合物。

13. 发明授权

US06300363B1 Indole compounds as COX-2 inhibitors 失效
标题翻译：吲哚化合物作为COX-2抑制剂
公开(公告)号：US06300363B1
公开(公告)日：2001-10-09
申请号：US09424837
申请日：1999-12-03
申请人： Rodney William Stevens , Kasumari Nakao , Kiyoshi Kawamura , Chikara Uchida , Shinya Fujiwara
发明人： Rodney William Stevens , Kasumari Nakao , Kiyoshi Kawamura , Chikara Uchida , Shinya Fujiwara
IPC分类号： A61K3140
CPC分类号： C07D401/06 , C07D209/40 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/06 , C07D405/12 , C07D409/06 , C07D409/12 , C07D413/06 , C07D413/12 , C07D417/06 , C07D417/12
摘要： This invention provides a compound of the following formula: and the pharmaceutically acceptable salts thereof, wherein L is oxygen or sulfur; Y is a direct bond or C1-4 alkylidene; Q is C1-6 alkyl, C3-7 cycloalkyl, phenyl, naphthyl, heteroaryl or the like; R1 is hydrogen, C1-6 alkyl or the like; R2 is hydrogen, C1-4 alkyl, C(O)R5 wherein R5 is C1-22 alkyl or C2-22 alkenyl, halosubstituted C1-8 alkyl, halosubstituted C2-8alkenyl, —Y—C3-7 cycloalkyl, —Y—C3-7 cycloalkenyl, phenyl, naphthyl, heteroaryl or the like; X is halo, C1-4 alkyl, hydroxy, C1-4 alkoxy or the like; and n is 0, 1, 2 or 3, with the proviso that a group of formula —Y—Q is not methyl or ethyl when X is hydrogen; L is oxygen; R1 is hydrogen; and R2 is acetyl. This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.
摘要翻译：本发明提供下式的化合物及其药学上可接受的盐，其中L是氧或硫; Y是直接键或C1-4亚烷基; Q为C 1-6烷基，C 3-7环烷基，苯基，萘基，杂芳基等; R1是氢，C1-6烷基等; R2是氢，C1-4烷基，C（O）R5，其中R5是C1-22烷基或C2-22链烯基，卤代C 1-8烷基，卤代C 2-8烯基，-Y-C 3-7环烷基，-Y-C 3 -7环烯基，苯基，萘基，杂芳基等; X是卤素，C 1-4烷基，羟基，C 1-4烷氧基等; 且n为0,1,2或3，条件是当X为氢时，式-Y-Q基团不是甲基或乙基; L是氧; R1是氢; 并且R 2是乙酰基。本发明还提供了可用于治疗前列腺素作为病原体的医学病症的药物组合物。

14. 发明申请

US20100144789A1 1-Isopropyl-2-Oxo-1,2-dihydropyridine-3-carboxamide Derivatives having 5-HT4 Receptor Agonistic Activity 失效
标题翻译：具有5-HT4受体激动活性的1-异丙基-2-氧代-1,2-二氢吡啶-3-甲酰胺衍生物
公开(公告)号：US20100144789A1
公开(公告)日：2010-06-10
申请号：US12708012
申请日：2010-02-18
申请人： Tomoki Kato , Kiyoshi Kawamura , Chikara Uchida
发明人： Tomoki Kato , Kiyoshi Kawamura , Chikara Uchida
IPC分类号： A61K31/4545 , C07D401/12 , A61P1/00 , A61P1/08 , A61P1/04 , A61P25/00 , A61P25/28 , A61P9/00 , A61P9/06
CPC分类号： C07D401/12 , C07D405/14
摘要： This invention provides a compound of formula (I): wherein R1 represents an alkyl group having from 1 to 4 carbon atoms or a halogen atom, R2 represents an alkyl group having from 1 to 4 carbon atoms, R3 represents a hydrogen atom or a hydroxy group, and A represents an oxygen atom or a group of the formula —C(R4)(R5)— (in which R4 represents a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms and R5 represents a hydroxy group or an alkoxy group having from 1 to 4 carbon atoms) or a pharmaceutically acceptable salts thereof. These compounds have 5-HT4 receptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.
摘要翻译：本发明提供式（I）化合物：其中R 1表示具有1至4个碳原子的烷基或卤原子，R 2表示具有1至4个碳原子的烷基，R 3表示氢原子或羟基基团，A表示氧原子或式-C（R4）（R5） - （其中R4表示氢原子或具有1至4个碳原子的烷基，R5表示羟基或式具有1至4个碳原子的烷氧基）或其药学上可接受的盐。这些化合物具有5-HT 4受体激动活性，因此可用于治疗哺乳动物特别是人类的胃食管反流病，非溃疡性消化不良，功能性消化不良，肠易激综合征等。

15. 发明授权

US07691881B2 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-HT4 receptor agonistic activity 失效
标题翻译：具有5-HT 4受体激动活性的1-异丙基-2-氧代-1,2-二氢吡啶-3-甲酰胺衍生物
公开(公告)号：US07691881B2
公开(公告)日：2010-04-06
申请号：US10597480
申请日：2005-01-18
申请人： Tomoki Kato , Kiyoshi Kawamura , Chikara Uchida
发明人： Tomoki Kato , Kiyoshi Kawamura , Chikara Uchida
IPC分类号： A61K31/445 , C07D401/12
CPC分类号： C07D401/12 , C07D405/14
摘要： This invention provides a compound of formula (I): wherein R1 represents an alkyl group having from 1 to 4 carbon atoms or a halogen atom, R2 represents an alkyl group having from 1 to 4 carbon atoms, R3 represents a hydrogen atom or a hydroxy group, and A represents an oxygen atom or a group of the formula —C(R4)(R5)— (in which R4 represents a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms and R5 represents a hydroxy group or an alkoxy group having from 1 to 4 carbon atoms) or a pharmaceutically acceptable salts thereof. These compounds have 5-HT4 receptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.
摘要翻译：本发明提供式（I）化合物：其中R 1表示具有1至4个碳原子的烷基或卤原子，R 2表示具有1至4个碳原子的烷基，R 3表示氢原子或羟基基团，A表示氧原子或式-C（R4）（R5） - （其中R4表示氢原子或具有1至4个碳原子的烷基，R5表示羟基或式具有1至4个碳原子的烷氧基）或其药学上可接受的盐。这些化合物具有5-HT 4受体激动活性，因此可用于治疗哺乳动物特别是人类的胃食管反流病，非溃疡性消化不良，功能性消化不良，肠易激综合征等。

16. 发明授权

US07595329B2 Benzimidazolone carboxylic acid derivatives 失效
标题翻译：苯并咪唑酮羧酸衍生物
公开(公告)号：US07595329B2
公开(公告)日：2009-09-29
申请号：US11153757
申请日：2005-06-14
申请人： Koji Ando , Satoru Iguchi , Noriaki Murase , Yoshinori Murata , Toyoharu Numata , Hiroki Sone , Chikara Uchida , Tatsuo Ueki
发明人： Koji Ando , Satoru Iguchi , Noriaki Murase , Yoshinori Murata , Toyoharu Numata , Hiroki Sone , Chikara Uchida , Tatsuo Ueki
IPC分类号： A61K31/445 , C07D401/12
CPC分类号： C07D401/12 , C07D211/26 , C07D401/06 , C07D401/14 , C07D405/06 , C07D405/14
摘要： This invention relates to compounds of the formula (I): wherein R1, R2, R3, A and m are each as described herein or a pharmaceutically acceptable salt or solvate thereof, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 receptor activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders such as cardiac failure and heart arrhythmia, diabetes and apnea syndrome.
摘要翻译：本发明涉及式（I）化合物：其中R 1，R 2，R 3，A和m各自如本文所述，或其药学上可接受的盐或溶剂化物，以及含有这些化合物的组合物和这些化合物在治疗中的用途由5-HT4受体活性介导的病症，例如但不限于胃食管反流病，胃肠道疾病，胃动力障碍，非溃疡性消化不良，功能性消化不良，肠易激综合征（IBS），便秘，消化不良，食道炎，胃肠疾病，恶心，中枢神经系统疾病，阿尔茨海默病，认知障碍，呕吐，偏头痛，神经系统疾病，疼痛，心血管疾病如心力衰竭和心律失常，糖尿病和呼吸暂停综合征。

17. 发明授权

US06979690B2 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators 失效
公开(公告)号：US06979690B2
公开(公告)日：2005-12-27
申请号：US10337497
申请日：2003-01-07
申请人： Geoffrey Gymer , Kiyoshi Kawamura , Sachiko Mihara , Mikio Morita , Alan Stobie , Chikara Uchida , Seiji Nukui
发明人： Geoffrey Gymer , Kiyoshi Kawamura , Sachiko Mihara , Mikio Morita , Alan Stobie , Chikara Uchida , Seiji Nukui
IPC分类号： A61K31/4545 , A61P1/00 , A61P1/04 , A61P1/08 , A61P1/10 , A61P1/14 , A61P9/00 , A61P9/10 , A61P25/00 , A61P25/04 , A61P25/06 , A61P25/22 , A61P25/28 , A61P43/00 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/14 , A61K31/445
CPC分类号： C07D401/06 , C07D401/12 , C07D401/14
摘要： This invention provides compounds of the formula (I) and (II): or the pharmaceutically acceptable esters thereof, and the pharmaceutically acceptable salts thereof: wherein R1 is hydrogen or halo; R2 and R3 are independently hydrogen or C1-6 alkyl; R4 and R5 are independently hydrogen or C1-6 alkyl; R6 is hydrogen, C1-12 alkyl, C1-6 alkoxy (C1-6)alkyl or C1-12 alkyl substituted by up to 3 substituents selected from the groups consisting of C3-8 cycloalkyl, aryl, heteroaryl and heterocyclic; R7 and R8 are hydrogen or taken together may form alkylene chain having one or two carbon atoms; R9 is C1-6 alkyl or C3-8 cycloalkyl; R10 is C1-6 alkyl or NR11R12; L is (CR11R12)n or NR11; M is NR11 or (CR11R12)n; R11 and R12 are independently hydrogen or C1-6 alkyl; n is an integer from 0 to 5; and m is an integer from 0 to 2; said heterocyclic, aryl and heteroaryl are unsubstituted or are substituted by at least one substituent selected from the group consisting of halo and C1-6 alkyl; with the proviso that when R9 is C1-6 alkyl, L is not NR11. These compounds have 5-HT4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.

18. 发明授权

US06951867B2 N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators 失效
标题翻译： N-取代的哌啶基 - 咪唑并吡啶化合物作为5-HT 4受体调节剂
公开(公告)号：US06951867B2
公开(公告)日：2005-10-04
申请号：US10667182
申请日：2003-09-17
申请人： Yasuhiro Katsu , Kana Kon-I , Mikio Morita , Hirohide Noguchi , Chikara Uchida
发明人： Yasuhiro Katsu , Kana Kon-I , Mikio Morita , Hirohide Noguchi , Chikara Uchida
IPC分类号： C07D471/04 , A61K31/437 , A61P1/04
CPC分类号： C07D471/04
摘要： This invention provides a compound of the formula (I): or a pharmaceutically acceptable salt, amide or ester thereof, wherein R1 represents a hydrogen atom or a halogen atom; R2 represents a hydrogen atom, etc.; R3 represents an alkyl group having from 1 to 10 carbon atoms; said alkyl group of R3 is substituted by at least one substituent selected from the group consisting of substituents α; said substituents α is aryl, hydroxy, oxo, etc.; said aryl having 6 to 10 carbon atoms; said aryl is unsubstituted or substituted by at least one alkyl group having from 1 to 6 carbon atoms; said heterocyclic and the heterocyclic moiety of said heterocycliccarbonyl, both of substituents α, are 5- to 10-membered cyclic groups containing from 1 to 4 heteroatoms selected from the group consisting of nitrogen atoms, oxygen atoms and sulfur atoms These compounds have 5-HT4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.
摘要翻译：本发明提供式（I）化合物或其药学上可接受的盐，酰胺或酯，其中R 1表示氢原子或卤素原子; R 2表示氢原子等; R 3表示具有1至10个碳原子的烷基; 所述R 3的烷基被至少一个选自取代基α的取代基取代; 所述取代基α是芳基，羟基，氧代等; 所述芳基具有6至10个碳原子; 所述芳基是未取代的或被至少一个具有1至6个碳原子的烷基取代; 所述杂环基和所述杂环羰基的杂环部分，两个取代基α为含有1至4个选自氮原子，氧原子和硫原子的杂原子的5至10元环基这些化合物具有5-HT 受体结合活性，因此可用于治疗哺乳动物，特别是人类的胃食管反流病，非溃疡性消化不良，功能性消化不良，肠易激综合征等。本发明还提供了包含上述化合物的药物组合物。

19. 发明申请

US20050148573A1 Benzimidazolone compounds having 5-HT4 receptor agonistic activity 有权
标题翻译：具有5-HT 4受体激动活性的苯并咪唑酮化合物
公开(公告)号：US20050148573A1
公开(公告)日：2005-07-07
申请号：US10933629
申请日：2004-09-02
申请人： Yasuhiro Katsu , Satoru Iguchi , Hiroki Sone , Chikara Uchida , Takashi Kojima
发明人： Yasuhiro Katsu , Satoru Iguchi , Hiroki Sone , Chikara Uchida , Takashi Kojima
IPC分类号： A61K31/454 , A61K31/46 , A61P1/04 , C07D401/12 , C07D405/06 , C07D405/14 , C07D413/14 , C07D451/02 , C07D471/04 , C07D43/02
CPC分类号： C07D413/14 , C04B35/632 , C07D401/12 , C07D405/06 , C07D405/14
摘要： This invention provides a compound of the formula (I): or a pharmaceutically acceptable salt thereof, and compositions containing such compounds and the use of such compounds for the manufacture of medicament for gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders, cardiac failure, heart arrhythmia, diabetes and apnea syndrome. These compounds have 5-HT4 receptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.
摘要翻译：本发明提供式（I）化合物或其药学上可接受的盐，以及含有这些化合物的组合物以及这些化合物在制备胃食管反流疾病，胃肠道疾病，胃动力障碍，非溃疡的药物中的用途消化不良，功能性消化不良，肠易激综合征（IBS），便秘，消化不良，食管炎，胃食管疾病，恶心，中枢神经系统疾病，阿尔茨海默病，认知障碍，呕吐，偏头痛，神经系统疾病，疼痛，心血管疾病，心力衰竭，心脏心律失常，糖尿病和呼吸暂停综合征。这些化合物具有5-HT 4受体激动活性，因此可用于治疗哺乳动物，特别是人类的胃食管反流病，非溃疡性消化不良，功能性消化不良，肠易激综合征等。

20. 发明授权

US06608070B1 2,3-substituted indole compounds as anti-inflammatory and analgesic agents 失效
标题翻译： 2,3-取代的吲哚化合物作为抗炎和止痛剂
公开(公告)号：US06608070B1
公开(公告)日：2003-08-19
申请号：US09355494
申请日：1999-07-28
申请人： Kazunari Nakao , Rodney William Stevens , Kiyoshi Kawamura , Chikara Uchida , Hiroki Koike , Stephane Caron
发明人： Kazunari Nakao , Rodney William Stevens , Kiyoshi Kawamura , Chikara Uchida , Hiroki Koike , Stephane Caron
IPC分类号： A01N4390
CPC分类号： C07D401/06 , C07D209/18 , C07D401/10 , C07D403/06 , C07D405/06 , C07D405/10 , C07D409/06 , C07D409/10 , C07D413/06 , C07D417/06 , C07D417/10
摘要： This invention provides a compound of the following formula: or the pharmaceutically acceptable salts thereof wherein Z is OH, C1-6 alkoxy, —NR2R3 or heterocycle; Q is selected from the following: (a) an optionally substituted phenyl, (b) an optionally substituted 6-membered monocyclic aromatic group containing one, two, three or four nitrogen atom(s), (c) an optionally substituted 5-membered monocyclic aromatic group containing one heteroatom selected from O, S and N and optionally containing one, two or three nitrogen atom(s) in addition to said heteroatom, (d) an optionally substituted C3-7 cycloalkyl and (e) an optionally substituted benzo-fuzed heterocycle; R1 is hydrogen, C1-4 alkyl or halo; R2 and R3 are independently hydrogen, OH, C1-4 alkoxy, C1-4 alkyl or C1-4 alkyl substituted with halo, OH, C1-4 alkoxy or CN; X is independently selected from H, halo, C1-4 alkyl, halo-substituted C1-4 alkyl, OH, C1-4 alkoxy, halo-substituted C1-4 alkoxy, C1-4 alkylthio, NO2, NH2, di-(C1-4 alkyl)amino and CN; and n is 0, 1, 2, 3 and 4. This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.
摘要翻译：本发明提供下式的化合物或其药学上可接受的盐，其中Z是OH，C 1-6烷氧基，-NR 2 R 3或杂环; Q选自以下：（a）任选取代的苯基，（b）含有一个，两个，三个或四个氮原子的任选取代的6元单环芳族基团，（c）任选取代的5元含有一个选自O，S和N的杂原子，并且除了所述杂原子之外任选含有一个，两个或三个氮原子的单环芳基，（d）任选取代的C 3-7环烷基和（e）任选取代的苯并杂环杂环 R1是氢，C1-4烷基或卤素; R2和R3独立地是氢，OH，C1-4烷氧基，C1-4烷基或被卤素，OH，C1-4烷氧基或CN取代的C1-4烷基; X独立地选自H，卤素，C 1-4烷基，卤素取代的C 1-4烷基，OH，C 1-4烷氧基，卤素取代的C 1-4烷氧基，C 1-4烷硫基，NO 2，NH 2，二（C 1 -4烷基）氨基和CN; 并且n为0,1,2,3和4.本发明还提供了可用于治疗前列腺素作为病原体的医疗状况的药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式